Monoclonal antibody therapy in multiple sclerosis

References

• Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372:1502 - 1517
   PubMed Web of Science ®Google Scholar
• Lublin F. History of modern multiple sclerosis therapy. J Neurol 2005; 252:3 - 9
   PubMed Web of Science ®Google Scholar
• Sospedra M, Martin R. Immunology of multiple sclerosis. Ann Rev Immunol 2005; 23:683 - 747
   PubMed Web of Science ®Google Scholar
• Bermel RA, Fisher E, Cohen JA. The use of MR imaging as an outcome measure in multiple sclerosis clinical trials. Neuroimaging Clin N Am 2008; 18:687 - 701
   PubMed Web of Science ®Google Scholar
• Menge T, Weber MS, Hemmer B, Kieseier BC, von Budingen HC, Warnke C, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008; 68:2445 - 2468
   PubMed Web of Science ®Google Scholar
• Clerico M, Contessa G, Durelli L. Interferon-beta1a for the treatment of multiple sclerosis. Expert Opin Biol Ther 2007; 7:535 - 542
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R. Multiple sclerosis therapeutics: unexpected outcomes clouding undisputed successes. Neurology 2009; 72:1008 - 1015
   PubMed Web of Science ®Google Scholar
• Klawiter EC, Cross AH, Naismith RT. The present efficacy of multiple sclerosis therapeutics: Is the new 66% just the old 33%?. Neurology 2009; 73:984 - 990
   PubMed Web of Science ®Google Scholar
• Steinman L, Martin R, Bernard C, Conlon P, Oksenberg JR. Multiple sclerosis: deeper understanding of its pathogenesis reveals new targets for therapy. Ann Rev Neurosci 2002; 25:491 - 505
   PubMed Web of Science ®Google Scholar
• Lopez-Diego RS, Weiner HL. Novel therapeutic strategies for multiple sclerosis—a multifaceted adversary. Nat Rev Drug Discov 2008; 7:909 - 925
   PubMed Web of Science ®Google Scholar
• Linker RA, Kieseier BC, Gold R. Identification and development of new therapeutics for multiple sclerosis. Trends Pharmacol Sci 2008; 29:558 - 565
   PubMed Web of Science ®Google Scholar
• Cohen JA. Emerging therapies for relapsing multiple sclerosis. Arch Neurol 2009; 66:821 - 828
   PubMed Web of Science ®Google Scholar
• Bielekova B, Becker BL. Monoclonal antibodies in MS: mechanisms of action. Neurology 2010; 74:31 - 40
   PubMed Web of Science ®Google Scholar
• Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler 2009; 15:189 - 192
   PubMed Web of Science ®Google Scholar
• Rudick RA, Mi S, Sandrock AW Jr. LINGO-1 antagonists as therapy for multiple sclerosis: in vitro and in vivo evidence. Expert Opin Biol Ther 2008; 8:1561 - 1570
   PubMed Web of Science ®Google Scholar
• Fontoura P, Steinman L. Nogo in multiple sclerosis: growing roles of a growth inhibitor. J Neurol Sci 2006; 245:201 - 210
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, Fox NC, Bullock R, Klunk WE, et al. (11)C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010; 9:363 - 372
   PubMed Web of Science ®Google Scholar
• Steinman L. The use of monoclonal antibodies for treatment of autoimmune disease. J Clin Immunol 1990; 10:30 - 38
   Web of Science ®Google Scholar
• Hohlfeld R, Wekerle H. Drug insight: using monoclonal antibodies to treat multiple sclerosis. Nat Clin Pract Neurol 2005; 1:34 - 44
   PubMedGoogle Scholar
• van Oosten BW, Barkhof F, Truyen L, Boringa JB, Bertelsmann FW, von Blomberg BM, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47:1531 - 1534
   PubMed Web of Science ®Google Scholar
• Wiendl H, Hohlfeld R. Therapeutic approaches in multiple sclerosis: lessons from failed and interrupted treatment trials. BioDrugs 2002; 16:183 - 200
   PubMed Web of Science ®Google Scholar
• Steinman L. Immune therapy for autoimmune diseases. Science 2004; 305:212 - 216
   PubMed Web of Science ®Google Scholar
• Weaver CT, Hatton RD, Mangan PR, Harrington LE. IL-17 family cytokines and the expanding diversity of effector T cell lineages. Ann Rev Immunol 2007; 25:821 - 852
   PubMed Web of Science ®Google Scholar
• El-Behi M, Rostami A, Ciric B. Current views on the roles of Th1 and Th17 cells in experimental autoimmune encephalomyelitis. J Neuroimmune Pharm 2010; 5:189 - 197
   PubMed Web of Science ®Google Scholar
• Segal BM, Constantinescu CS, Raychaudhuri A, Kim L, Fidelus-Gort R, Kasper LH. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study. Lancet Neurol 2008; 7:796 - 804
   PubMed Web of Science ®Google Scholar
• Elliott M, Benson J, Blank M, Brodmerkel C, Baker D, Sharples KR, et al. Ustekinumab: lessons learned from targeting interleukin-12/23p40 in immune-mediated diseases. Ann NY Acad Sci 2009; 1182:97 - 110
   PubMed Web of Science ®Google Scholar
• Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008; 7:538 - 547
   PubMed Web of Science ®Google Scholar
• Buttmann M, Rieckmann P. Treating multiple sclerosis with monoclonal antibodies. Expert Rev Neurother 2008; 8:433 - 455
   PubMedGoogle Scholar
• Rose JW, Foley JF, Carlson NG. Monoclonal antibody treatments for multiple sclerosis. Curr Treat Options Neurol 2009; 11:211 - 220
   PubMed Web of Science ®Google Scholar
• Ransohoff RM. Natalizumab for multiple sclerosis. New Engl J Med 2007; 356:2622 - 2629
   PubMed Web of Science ®Google Scholar
• Johnson KP. Natalizumab (Tysabri) treatment for relapsing multiple sclerosis. Neurologist 2007; 13:182 - 187
   PubMed Web of Science ®Google Scholar
• Engelhardt B, Ransohoff RM. The ins and outs of T-lymphocyte trafficking to the CNS: anatomical sites and molecular mechanisms. Trends Immunol 2005; 26:485 - 495
   PubMed Web of Science ®Google Scholar
• Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman L, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha4beta1 integrin. Nature 1992; 356:63 - 66
   PubMed Web of Science ®Google Scholar
• Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov 2005; 4:510 - 518
   PubMed Web of Science ®Google Scholar
• Polman CH, O'Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New Engl J Med 2006; 354:899 - 910
   PubMed Web of Science ®Google Scholar
• Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. New Engl J Med 2006; 354:911 - 923
   PubMed Web of Science ®Google Scholar
• Rice GP, Hartung HP, Calabresi PA. Anti-alpha4 integrin therapy for multiple sclerosis: mechanisms and rationale. Neurology 2005; 64:1336 - 1342
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, et al. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis. Arch Neurol 2006; 63:1383 - 1387
   PubMed Web of Science ®Google Scholar
• Stuve O, Marra CM, Jerome KR, Cook L, Cravens PD, Cepok S, et al. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol 2006; 59:743 - 747
   PubMed Web of Science ®Google Scholar
• Niino M, Bodner C, Simard ML, Alatab S, Gano D, Kim HJ, et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006; 59:748 - 754
   PubMed Web of Science ®Google Scholar
• del Pilar Martin M, Cravens PD, Winger R, Frohman EM, Racke MK, Eagar TN, et al. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol 2008; 65:1596 - 1603
   PubMed Web of Science ®Google Scholar
• Li YY, Perez HD, Zollner TM. Fatalities in natalizumab treatment—a ‘no go’ for leukocyte recirculation approaches?. Expert Opin Ther Targets 2006; 10:489 - 499
   PubMed Web of Science ®Google Scholar
• Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007; 6:431 - 441
   PubMed Web of Science ®Google Scholar
• Clifford DB, Deluca A, Simpson DM, Arendt G, Giovannoni G, Nath A. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 2010; 9:438 - 446
   PubMed Web of Science ®Google Scholar
• Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008; 71:766 - 773
   PubMed Web of Science ®Google Scholar
• Brickelmaier M, Lugovskoy A, Kartikeyan R, Reviriego-Mendoza MM, Allaire N, Simon K, et al. Identification and characterization of mefloquine efficacy against JC virus in vitro. Antimicrob Agents Ch 2009; 53:1840 - 1849
   PubMed Web of Science ®Google Scholar
• Elphick GF, Querbes W, Jordan JA, Gee GV, Eash S, Manley K, et al. The human polyomavirus, JCV, uses serotonin receptors to infect cells. Science 2004; 306:1380 - 1383
   PubMed Web of Science ®Google Scholar
• Schweikert A, Kremer M, Ringel F, Liebig T, Duyster J, Stuve O, et al. Primary central nervous system lymphoma in a patient treated with natalizumab. Ann Neurol 2009; 66:403 - 406
   PubMed Web of Science ®Google Scholar
• Bergamaschi R, Montomoli C. Melanoma in multiple sclerosis treated with natalizumab: causal association or coincidence?. Mult Scler 2009; 15:1532 - 1533
   PubMed Web of Science ®Google Scholar
• Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. P Natl Acad Sci USA 2006; 103:5941 - 5946
   PubMed Web of Science ®Google Scholar
• Oh U, Blevins G, Griffith C, Richert N, Maric D, Lee CR, et al. Regulatory T cells are reduced during anti-CD25 antibody treatment of multiple sclerosis. Arch Neurol 2009; 66:471 - 479
   PubMed Web of Science ®Google Scholar
• Bielekova B, Richert N, Howard T, Blevins G, Markovic-Plese S, McCartin J, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. P Natl Acad Sci USA 2004; 101:8705 - 8708
   PubMed Web of Science ®Google Scholar
• Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66:483 - 489
   PubMed Web of Science ®Google Scholar
• Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9:381 - 390
   PubMed Web of Science ®Google Scholar
• Coles AJ, Cox A, Le Page E, Jones J, Trip SA, Deans J, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253:98 - 108
   PubMed Web of Science ®Google Scholar
• Coles AJ, Wing M, Smith S, Coraddu F, Greer S, Taylor C, et al. Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis. Lancet 1999; 354:1691 - 1695
   PubMed Web of Science ®Google Scholar
• Coles AJ, Compston DA, Selmaj KW, Lake SL, Moran S, Margolin DH, et al. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. New Engl J Med 2008; 359:1786 - 1801
   PubMed Web of Science ®Google Scholar
• Jones JL, Phuah CL, Cox AL, Thompson SA, Ban M, Shawcross J, et al. IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H). J Clin Invest 2009; 119:2052 - 2061
   PubMed Web of Science ®Google Scholar
• Hutas G. Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies. Curr Opin Invest Dr 2008; 9:1206 - 1215
   PubMed Web of Science ®Google Scholar
• Castillo J, Milani C, Mendez-Allwood D. Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders. Expert Opin Inv Drug 2009; 18:491 - 500
   PubMed Web of Science ®Google Scholar
• Franciotta D, Salvetti M, Lolli F, Serafini B, Aloisi F. B cells and multiple sclerosis. Lancet Neurol 2008; 7:852 - 858
   PubMed Web of Science ®Google Scholar
• Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008; 4:557 - 567
   PubMedGoogle Scholar
• Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 2007; 130:1089 - 1104
   PubMed Web of Science ®Google Scholar
• Kutzelnigg A, Lucchinetti CF, Stadelmann C, Bruck W, Rauschka H, Bergmann M, et al. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128:2705 - 2712
   PubMed Web of Science ®Google Scholar
• McLaughlin KA, Wucherpfennig KW. B cells and autoantibodies in the pathogenesis of multiple sclerosis and related inflammatory demyelinating diseases. Adv Immunol 2008; 98:121 - 149
   Google Scholar
• Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. New Engl J Med 2008; 358:676 - 688
   PubMed Web of Science ®Google Scholar
• Martin MP, Cravens PD, Winger R, Kieseier BC, Cepok S, Eagar TN, et al. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab. Arch Neurol 2009; 66:1016 - 1020
   PubMed Web of Science ®Google Scholar
• Hawker K, O'Connor P, Freedman MS, Calabresi PA, Antel J, Simon J, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66:460 - 471
   PubMed Web of Science ®Google Scholar
• Pittock SJ. Neuromyelitis optica: a new perspective. Sem Neurol 2008; 28:95 - 104
   PubMed Web of Science ®Google Scholar
• Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65:1443 - 1448
   PubMed Web of Science ®Google Scholar
• Fillatreau S, Gray D, Anderton SM. Not always the bad guys: B cells as regulators of autoimmune pathology. Nat Rev Immunol 2008; 8:391 - 397
   PubMed Web of Science ®Google Scholar
• Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, et al. Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis. J Immunol 2007; 178:6092 - 6099
   PubMed Web of Science ®Google Scholar
• Fontoura P. Roles of B lymphocytes in Multiple Sclerosis: diversifying beyond the antibody response. Immunotherapy 2009; 1:181 - 185
   Google Scholar
• Carson KR, Evens AM, Richey EA, Habermann TM, Focosi D, Seymour JF, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009; 113:4834 - 4840
   PubMed Web of Science ®Google Scholar
• Major EO. Progressive Multifocal leukoencephalopathy in patients on immunomodulatory therapies. Ann Review Med 2010; 61:35 - 47
   PubMed Web of Science ®Google Scholar
• Weber T. Progressive multifocal leukoencephalopathy. Neurol Clin 2008; 26:833 - 854
   PubMed Web of Science ®Google Scholar
• Berger JR. Progressive multifocal leukoencephalopathy. Curr Neurol Neurosci Rep 2007; 7:461 - 469
   PubMed Web of Science ®Google Scholar
• Tan CS, Dezube BJ, Bhargava P, Autissier P, Wuthrich C, Miller J, et al. Detection of JC virus DNA and proteins in the bone marrow of HIV-positive and HIV-negative patients: implications for viral latency and neurotropic transformation. J Infect Dis 2009; 199:881 - 888
   PubMed Web of Science ®Google Scholar
• Sabath BF, Major EO. Traffic of JC virus from sites of initial infection to the brain: the path to progressive multifocal leukoencephalopathy. J Infect Dis 2002; 186:180 - 186
   PubMed Web of Science ®Google Scholar
• Lindberg RL, Achtnichts L, Hoffmann F, Kuhle J, Kappos L. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol 2008; 194:153 - 164
   PubMed Web of Science ®Google Scholar
• Berger JR, Houff SA, Major EO. Monoclonal antibodies and progressive multifocal leukoencephalopathy. MAbs 2009; 1:583 - 589
   PubMed Web of Science ®Google Scholar
• Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the Research on Adverse Drug Events and Reports (RADAR) Project. Lancet Oncol 2009; 10:816 - 824
   PubMed Web of Science ®Google Scholar
• Krumbholz M, Meinl I, Kumpfel T, Hohlfeld R, Meinl E. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71:1350 - 1354
   PubMed Web of Science ®Google Scholar
• Molloy ES, Calabrese LH. Progressive multifocal leukoencephalopathy in patients with rheumatic diseases: are patients with systemic lupus erythematosus at particular risk?. Autoimmun Rev 2008; 8:144 - 146
   PubMed Web of Science ®Google Scholar
• Hartman EA, Huang D. Update on PML: lessons from the HIV uninfected and new insights in pathogenesis and treatment. Current HIV/AIDS Reports 2008; 5:112 - 119
   PubMedGoogle Scholar
• Chen Y, Bord E, Tompkins T, Miller J, Tan CS, Kinkel RP, et al. Asymptomatic reactivation of JC virus in patients treated with natalizumab. New Engl J Med 2009; 361:1067 - 1074
   PubMed Web of Science ®Google Scholar
• Jilek S, Jaquiery E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, et al. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study. Lancet Neurol 2010; 9:264 - 272
   PubMed Web of Science ®Google Scholar